Cellectis (CLLS) Revenue (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.57% |
| Dec 31, 2025 | -63.85% |
| Sep 30, 2025 | 110.30% |
| Jun 30, 2025 | 56.97% |
| Mar 31, 2025 | -47.84% |
| Dec 31, 2024 | 26.10% |
| Sep 30, 2024 | 100.97% |
| Jun 30, 2024 | 78.03% |
| Mar 31, 2024 | 1,500.00% |
| Dec 31, 2023 | 82.58% |
| Sep 30, 2023 | -12.92% |
| Jun 30, 2023 | 28.06% |
| Mar 31, 2023 | -99.13% |
| Dec 31, 2022 | 9,056.57% |
| Sep 30, 2022 | -86.61% |
| Jun 30, 2022 | -21.50% |
| Mar 31, 2022 | -83.78% |
| Dec 31, 2021 | 23.46% |
| Sep 30, 2021 | -25.63% |
| Jun 30, 2021 | -56.35% |
| Mar 31, 2021 | 87.57% |
| Dec 31, 2020 | 120.89% |
| Sep 30, 2020 | 113.07% |
| Jun 30, 2020 | -94.21% |
| Mar 31, 2020 | 1,033.35% |
| Dec 31, 2019 | -47.89% |
| Sep 30, 2019 | 636.72% |
| Jun 30, 2019 | 11.20% |
| Mar 31, 2019 | 7.02% |
| Dec 31, 2018 | 6.84% |
| Sep 30, 2018 | -82.06% |
| Jun 30, 2018 | -16.41% |
| Mar 31, 2018 | -12.59% |
| Dec 31, 2017 | 12.87% |
| Sep 30, 2017 | -5.73% |
| Jun 30, 2017 | -3.62% |
| Mar 31, 2017 | -17.82% |
| Dec 31, 2016 | -27.22% |
| Sep 30, 2016 | 1,570.19% |
| Jun 30, 2016 | -91.24% |
| Mar 31, 2016 | -78.74% |
| Dec 31, 2015 | 328.28% |
| Sep 30, 2015 | 4.38% |
| Jun 30, 2015 | -14.95% |